Evidence map›Paper›PMID 26839072›Full record

ArticleBeneficial microbes2016

High purity galacto-oligosaccharides enhance specific Bifidobacterium species and their metabolic activity in the mouse gut microbiome.

A Monteagudo-Mera, J C Arthur, C Jobin, T Keku, J M Bruno-Barcena, M A Azcarate-Peril

Open access · greenAbstract read
In one paragraph

Article in Beneficial microbes, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 1 pooled it
7.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 1 synthesis or guideline pooled it, 108 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Impact of short-chain galactooligosaccharides on the gut microbiome of lactose-intolerant individuals.Proceedings of the National Academy of Sciences of the United States of America · 2017
    Trial
  6. Trial
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Current research in food science · 2025
    Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

A Monteagudo-Mera1 Microbiome Core Facility, Center for Gastrointestinal Biology and Disease, University of North Carolina, 312 Isaac Taylor Hall, Chapel Hill, NC 27599, USA.
J C Arthur2 Department of Medicine, Division of Gastroenterology and Hepatology and Center for Gastrointestinal Biology and Disease, University of North Carolina, 312 Isaac Taylor Hall, Chapel Hill, NC 27599, USA.
C Jobin2 Department of Medicine, Division of Gastroenterology and Hepatology and Center for Gastrointestinal Biology and Disease, University of North Carolina, 312 Isaac Taylor Hall, Chapel Hill, NC 27599, USA.
T Keku2 Department of Medicine, Division of Gastroenterology and Hepatology and Center for Gastrointestinal Biology and Disease, University of North Carolina, 312 Isaac Taylor Hall, Chapel Hill, NC 27599, USA.
J M Bruno-Barcena4 Department of Plant and Microbial Biology, 4550A Thomas Hall, Campus Box 7615, Raleigh, NC 27695, USA.
M A Azcarate-Peril1 Microbiome Core Facility, Center for Gastrointestinal Biology and Disease, University of North Carolina, 312 Isaac Taylor Hall, Chapel Hill, NC 27599, USA.
University of North Carolina at Chapel Hill · US

Funding

PILOT AND FEASIBILITY STUDIESP30DK034987 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ROBERT S. SANDLER · 1985 to 2026
$30.5M
Intestinal inflammation and genotoxicity of the colonic-adherent microbiotaK01DK103952 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ARTHUR, JANELLE C · 2014 to 2018
$758k
NIDDK NIH HHS K01 DK103952NIDDK NIH HHS P30 DK034987NIDDK NIH HHS P30DK34987
6 · The paper itself

Abstract

Prebiotics are selectively fermented ingredients that result in specific changes in the composition and/or activity of the gastrointestinal microbiota, thus conferring benefit(s) upon the host health. The aim of this study was to evaluate the influence of a β(1-4)galacto-oligosaccharides (GOS) formulation consisting of 90% pure GOS (GOS90), on the composition and activity of the mouse gut microbiota. Germ-free mice were colonised with microbiota from four pathogen-free wt 129 mice donors (SPF), and stools were collected during a feeding trial in which GOS90 was delivered orally for 14 days. Pyrosequencing of 16S rDNA amplicons showed that Bifidobacterium and specific Lactobacillus, Bacteroides and Clostridiales were more prevalent in GOS90-fed mice after 14 days, although the prebiotic impact on Bifidobacterium varied among individual mice. Prebiotic feeding also resulted in decreased abundance of Bacteroidales, Helicobacter and Clostridium. High-throughput quantitative PCR showed an increased abundance of Bifidobacterium adolescentis, Bifidobacterium pseudocatenulatum, Bifidobacterium lactis and Bifidobacterium gallicum in the prebiotic-fed mice. Control female mice showed a higher diversity (phylogenetic diversity (PD) = 15.1 ± 3.4 in stools and PD = 13.0 ± 0.6 in intestinal contents) than control males (PD = 7.8 ± 1.6 in stool samples and PD = 9.5 ± 1.0 in intestinal contents). GOS90 did not modify inflammatory biomarkers (interleukin (IL)-6, IL-12, IL-1β, interferon gamma and tumour necrosis factor alpha). Decreased butyrate, acetate and lactate concentrations in stools of prebiotic fed mice suggested an increase in colonic absorption and reduced excretion. Overall, our results demonstrate that GOS90 is capable of modulating the intestinal microbiome resulting in expansion of the probiome (autochtonous commensal intestinal bacteria considered to have a beneficial influence on health).

Indexed as

Gastrointestinal MicrobiomeAnimalsBacteriaBifidobacteriumFemaleFermentationGalactoseGastrointestinal TractInterleukin-12Interleukin-6MaleMiceMice, 129 StrainOligosaccharidesPrebioticsGalactoseInterleukin-12Interleukin-6OligosaccharidesPrebioticsBifidobacteriummouse gut microbiomeprebiotics

Identifiers

PMID26839072
PMCPMC4974821
OpenAlexW2262506242

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.